Category Archives: Genetic medicine

Dr. Jos Rafael Yunn, an infectologist, and intensivist, considered yesterday that if the behavior of covid-19 continues on the same trajectory in the country, the gradual opening of the economy can begin in two weeks. He assured that the low mortality from covid-19, less than 1%, could be due to multiple explanations, genetic or of treatments that have been applied.

If the behavior of the epidemic in the country does not change in the next two weeks, we could gradually open the confinement, always protecting vulnerable people, he said. He believes that the opening of the economy should be started using intelligent measures of social distancing, and penalizing if they are not carried out through the use of continuous surveillance.

The critical medicine expert assures that the case fatality rate in the Dominican Republic has not increased, even with a high positivity rate.When analyzing the number of patients in intensive care units, based on real-time, it is 1.8%. The expert and member of the high-level commission that manages the issue said that the opening process should be carried out, protecting vulnerable people.

Yunn considers that everything must be done evaluating the number of cases, the percentage of occupancy of beds, and the percentage of lethality, in a systematic and constant way.

The main hypothesis is that the behavior of covid-19 could be related to issues such as climate, previous vaccination against tuberculosis with BCG, cross-reaction with other viruses such as zika, dengue, and chikungunya. It could also be explained in the use of such criticized treatments as Hydroxychloroquine or Ivermectin.

Could the disease and lethality behavior of covid-19 be due to vitamin D levels? asks the specialist.Is it also the genetic factors, is the stability the result of appropriate early quarantine or the sum of all? He asks.

Yesterdays report from the General Directorate of Epidemiology reported that the country already registers 11,739 positive cases (419 new ones), of which 1,885 people are in hospital isolation and 5,873 in-home isolation; visits are made to the latter for face-to-face monitoring, as well as telephone assistance and delivery of the indicated medications.

Only 127 of hospitalized patients are in intensive care units (ICU). The positivity rate in the samples processed during the last four weeks is 21.30%. Measures the specialists and authorities keep in place are the recommendations to the population to maintain a distance of at least one meter between two people. Also, the use of masks in work and public spaces. Care and isolation at the home of people with mild signs and symptoms.

It is recommended to seek care in health centers if you have a fever, headache, sore throat, diarrhea, loss of smell, malaise, cough, and respiratory distress.

To doctors, Yunn warned they refrain from doing ego-based medicine, and instead employ an evidence-based medicine.He assured that the low mortality, less than 1% by covid-19, could be due to multiple explanations, genetic, environmental, measures, or treatment regimes, in Dominicans.

The critical medicine expert referred to the warning made by his infectious colleagues about the use of treatments such as Ivermectin and other therapeutic options to treat covid-19. There is no justification right now for sending letters between medical societies without a proposal that offers solutions, he said.

In his opinion, what should be done in the medical community is to evaluate the protocols that are currently being applied and then, according to the lessons learned, carry out clinical trials to guide their effectiveness. Otherwise we would be promoting an ego-based medicine and not evidence-based collaborative medicine, said the expert.

It was asked what use is the state of confinement to which the countrys regulatory bodies have subjected the population if medical practice is frequently reversed.The lethality has not been so excessive.

The Society Infectious Diseases group expressed concern about the possibility that Ivermectin could be used as one of the therapeutic options to treat covid-19. MostSociety of Infectology members state that the use of parenteral Ivermectin should not even be weighted for the regular treatment of covid-19.

See original here:
Doctor believes Dominican Republic's economy could open in two weeks - Dominican Today

Catmint emits the odor nepetalactone which triggers a kind of ecstasy in sexually mature cats: They get high on sniffing at catmint plants, roll on the floor and exhibit an unusually playful behavior. Credit: Phil Robinson, John Innes Centre, Norwich, UK

Researchers discover the evolutionary origins of the cat attractant nepetalactone.

Catmint, also known as catnip, is well-known for its intoxicating effect on cats. The odor responsible for the cats strange behavior is nepetalactone, a volatile iridoid produced by catmint.

An international team of researchers has now found through genome analysis that the ability to produce iridoids had already been lost in ancestors of catmint in the course of evolution. Hence, nepetalactone biosynthesis is the result of repeated evolution. Nevertheless, this particular iridoid differs considerably from other compounds in this group of natural products with regards to its chemical structure and properties, and most likely its ecological functions (Science Advances).

Iridoids are plant secondary metabolites from the group of terpenes. Many plants produce these substances to defend themselves against herbivores or to protect themselves from pathogens, among these plants many species from the mint family (Lamiaceae). The ancestors of a particularly species-rich subfamily of the Lamiaceae, the Nepetoideae, which includes many well-known herbs, such as basil, oregano, rosemary, lemon balm, and mint, had lost the ability to produce iridoids in the course of evolution.

However, there is an important exception: the genus Nepeta, called catmint or catnip. Catmint plants produce iridoids including a very special form: nepetalactone, a volatile substance known to excite cats. Presumably, its actual function is to deter herbivores from trying to feed on catmint.

Catmint (Nepeta cataria), also called catnip, from the genus Nepeta belongs to the Lamiaceae family. It is well-known for its effect on cats. However, it is not clear why cats respond to the odor nepetalactone. Credit: Phil Robinson, John Innes Centre, Norwich, UK

An international team of researchers led by Sarah OConnor, director of the Department of Natural Product Biosynthesis at the Max Planck Institute for Chemical Ecology in Jena, Germany, has now investigated how and why catmint makes nepetalactone and how the biosynthetic pathways for the formation of this unique chemical molecule have evolved.

To answer this question, they sequenced the genome of catmint. We discovered a suite of unusual enzymes that generate nepetalactone molecules. These enzymes are not found in any related plant species and have evolved uniquely in catmint. When we first saw the genome sequence of catmint we realized that the important genes that we hypothesized were active in the formation of nepetalactone were next to each other in the genome. This allowed us to solve the problem more easily, explains Benjamin Lichman from the University of York, who is the first author of the study.

The scientists compared the genome of two catmint species which are both able to produce nepetalactone to the closely related medicinal plant hyssop (Hyssopus officinalis) which is neither able to produce nepetalactone nor any other iridoids. This comparative approach, the reconstruction of ancient genes, as well as comprehensive phylogenetic analyses enabled the researchers to understand the chronology of events that led to the emergence of nepetalactone biosynthesis. They were able to determine the mechanisms for the loss and subsequent re-evolution of iridoid biosynthesis in catmint. These new discoveries provide broader lessons in the evolution of plant metabolic novelty and diversity.

In particular, the nepetalactone pathway is found as a gene cluster, a group of similar genes located in the immediate vicinity in the genome. By looking at this cluster, together with gene fossils and resurrected ancient enzymes the scientists elucidated important steps that led to the formation of this cluster. Similar steps lead to the evolution of the impressive plant metabolic diversity in many plant lineages.

Catmint provides a great model example for studying these processes. We are now trying to modify the chemicals present in the catmint plants. This will help us know if we completely understand all aspects of the pathway as well as understand the ecological functions of nepetalactone. This can in turn help us to uncover the selective pressures that led to loss and regain of this pathway. We are also looking at other Nepeta species that produce unusual iridoids, says Sarah OConnor summarizing her future research plans.

The leader of the study has been the new director and head of the Department of Natural Product Biosynthesis at the Max Planck Institute for Chemical Ecology in Jena, Germany, since last year. The focus of her research is on the biosynthesis of plant metabolic products which do not only have multiple ecological roles in mediating a plants interactions with its environment, but also hold promising potential in medicine. She wants to understand how and why plants apply such complex chemical reactions to produce this fascinating diversity of molecules: Plants are constantly evolving new chemistry. With our research, we would like to get snapshots of this evolution in action.

###

Reference: The evolutionary origins of the cat attractant nepetalactone in catnip by Benjamin R. Lichman, Grant T. Godden, John P. Hamilton, Lira Palmer, Mohamed O. Kamileen, Dongyan Zhao, Brieanne Vaillancourt, Joshua C. Wood, Miao Sun, Taliesin J. Kinser, Laura K. Henry, Carlos Rodriguez-Lopez, Natalia Dudareva, Douglas E. Soltis, Pamela S. Soltis, C. Robin Buell and Sarah E. OConnor, 13 May 2020, Science Advances.DOI: 10.1126/sciadv.aba0721

This research was funded by the Mint Genome Project (National Science Foundation) led by C. Robin Buell at Michigan State University.

Link:
Genetic Analysis Reveals the Fascinating Evolutionary Origins of Catmint AKA Catnip - SciTechDaily

Los Angeles, United StatesThe report offers an all-inclusive and accurate research study on the global CRISPR And CRISPR-Associated (Cas) Genes market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the thorough market analysis provided in the report. The authors of the report have compiled a detailed study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to get a good understanding of future development of the global CRISPR And CRISPR-Associated (Cas) Genes market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to help with comprehensive evaluation of the global CRISPR And CRISPR-Associated (Cas) Genes market.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include : , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1704011/covid-19-impact-on-global-crispr-and-crispr-associated-cas-genes-market

Segment Analysis

The segmental analysis will help companies to focus on high-growth areas of the global CRISPR And CRISPR-Associated (Cas) Genes market. In order to broaden the overall understanding of the global CRISPR And CRISPR-Associated (Cas) Genes industry, the report has segregated the global CRISPR And CRISPR-Associated (Cas) Genes business into varied segments comprising product type, application, and end user. This examination has been carried out based on parameters like size, CAGR, share, production, and consumption. Also, region-wise assessment, wherein lucrative prospects that a region or country is likely to offer has been explored.

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment By Type:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering CRISPR And CRISPR-Associated (Cas) Genes

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment By Application:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering CRISPR And CRISPR-Associated (Cas) Genes

Competitive Landscape:

It is important for every market participant to be familiar with the competitive scenario in the global CRISPR And CRISPR-Associated (Cas) Genes industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include : , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes

Key Questions Answered

Enquire for Customization in this Report: https://www.qyresearch.com/customize-request/form/1704011/covid-19-impact-on-global-crispr-and-crispr-associated-cas-genes-market

Table of Contents

1 Study Coverage1.1 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction1.2 Market Segments1.3 Key CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type1.4.2 Genome Editing1.4.3 Genetic engineering1.4.4 gRNA Database/Gene Librar1.4.5 CRISPR Plasmid1.4.6 Human Stem Cells1.4.7 Genetically Modified Organisms/Crops1.4.8 Cell Line Engineering1.5 Market by Application1.5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application1.5.2 Biotechnology Companies1.5.3 Pharmaceutical Companies1.5.4 Academic Institutes1.5.5 Research and Development Institutes1.6 Coronavirus Disease 2019 (Covid-19): CRISPR And CRISPR-Associated (Cas) Genes Industry Impact1.6.1 How the Covid-19 is Affecting the CRISPR And CRISPR-Associated (Cas) Genes Industry

1.6.1.1 CRISPR And CRISPR-Associated (Cas) Genes Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and CRISPR And CRISPR-Associated (Cas) Genes Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for CRISPR And CRISPR-Associated (Cas) Genes Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Estimates and Forecasts2.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue 2015-20262.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales 2015-20262.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size by Region: 2020 Versus 20262.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global CRISPR And CRISPR-Associated (Cas) Genes Competitor Landscape by Players3.1 CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers3.1.1 CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers (2015-2020)3.1.2 CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Manufacturers (2015-2020)3.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers3.2.1 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers (2015-2020)3.2.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2015-2020)3.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by CRISPR And CRISPR-Associated (Cas) Genes Revenue in 20193.2.5 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Manufacturers3.4 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Base Distribution, Product Types3.4.1 CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Product Type3.4.3 Date of International Manufacturers Enter into CRISPR And CRISPR-Associated (Cas) Genes Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Type (2015-2020)4.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Type (2015-2020)4.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Type (2015-2020)4.1.3 CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) by Type (2015-2026)4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Type (2021-2026)4.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Type (2021-2026)4.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Type (2021-2026)4.2.3 CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Application (2015-2020)5.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Application (2015-2020)5.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Application (2015-2020)5.1.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Application (2015-2020)5.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Application (2021-2026)5.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Application (2021-2026)5.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Application (2021-2026)5.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price Forecast by Application (2021-2026) 6 North America6.1 North America CRISPR And CRISPR-Associated (Cas) Genes by Country6.1.1 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country6.1.2 North America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type6.3 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 7 Europe7.1 Europe CRISPR And CRISPR-Associated (Cas) Genes by Country7.1.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country7.1.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type7.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes by Region8.1.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region8.1.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type8.3 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 9 Latin America9.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes by Country9.1.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country9.1.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type9.3 Central & South America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes by Country10.1.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country10.1.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE10.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type10.3 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 11 Company Profiles11.1 Caribou Biosciences11.1.1 Caribou Biosciences Corporation Information11.1.2 Caribou Biosciences Description, Business Overview and Total Revenue11.1.3 Caribou Biosciences Sales, Revenue and Gross Margin (2015-2020)11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.1.5 Caribou Biosciences Recent Development11.2 Addgene11.2.1 Addgene Corporation Information11.2.2 Addgene Description, Business Overview and Total Revenue11.2.3 Addgene Sales, Revenue and Gross Margin (2015-2020)11.2.4 Addgene CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.2.5 Addgene Recent Development11.3 CRISPR THERAPEUTICS11.3.1 CRISPR THERAPEUTICS Corporation Information11.3.2 CRISPR THERAPEUTICS Description, Business Overview and Total Revenue11.3.3 CRISPR THERAPEUTICS Sales, Revenue and Gross Margin (2015-2020)11.3.4 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.3.5 CRISPR THERAPEUTICS Recent Development11.4 Merck KGaA11.4.1 Merck KGaA Corporation Information11.4.2 Merck KGaA Description, Business Overview and Total Revenue11.4.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)11.4.4 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.4.5 Merck KGaA Recent Development11.5 Mirus Bio LLC11.5.1 Mirus Bio LLC Corporation Information11.5.2 Mirus Bio LLC Description, Business Overview and Total Revenue11.5.3 Mirus Bio LLC Sales, Revenue and Gross Margin (2015-2020)11.5.4 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.5.5 Mirus Bio LLC Recent Development11.6 Editas Medicine11.6.1 Editas Medicine Corporation Information11.6.2 Editas Medicine Description, Business Overview and Total Revenue11.6.3 Editas Medicine Sales, Revenue and Gross Margin (2015-2020)11.6.4 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.6.5 Editas Medicine Recent Development11.7 Takara Bio USA11.7.1 Takara Bio USA Corporation Information11.7.2 Takara Bio USA Description, Business Overview and Total Revenue11.7.3 Takara Bio USA Sales, Revenue and Gross Margin (2015-2020)11.7.4 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.7.5 Takara Bio USA Recent Development11.8 Thermo Fisher Scientific11.8.1 Thermo Fisher Scientific Corporation Information11.8.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue11.8.3 Thermo Fisher Scientific Sales, Revenue and Gross Margin (2015-2020)11.8.4 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.8.5 Thermo Fisher Scientific Recent Development11.9 Horizon Discovery Group11.9.1 Horizon Discovery Group Corporation Information11.9.2 Horizon Discovery Group Description, Business Overview and Total Revenue11.9.3 Horizon Discovery Group Sales, Revenue and Gross Margin (2015-2020)11.9.4 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.9.5 Horizon Discovery Group Recent Development11.10 Intellia Therapeutics11.10.1 Intellia Therapeutics Corporation Information11.10.2 Intellia Therapeutics Description, Business Overview and Total Revenue11.10.3 Intellia Therapeutics Sales, Revenue and Gross Margin (2015-2020)11.10.4 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.10.5 Intellia Therapeutics Recent Development11.1 Caribou Biosciences11.1.1 Caribou Biosciences Corporation Information11.1.2 Caribou Biosciences Description, Business Overview and Total Revenue11.1.3 Caribou Biosciences Sales, Revenue and Gross Margin (2015-2020)11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.1.5 Caribou Biosciences Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Region12.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Regions 2021-202612.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Regions 2021-202612.2 North America CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.2.1 North America: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.2.2 North America: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.2.3 North America: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.3.1 Europe: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.3.2 Europe: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.3.3 Europe: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.4 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.4.1 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.4.2 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.4.3 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Region (2021-2026)12.5 Latin America CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.5.1 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.5.2 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.5.3 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.6.2 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key CRISPR And CRISPR-Associated (Cas) Genes Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 CRISPR And CRISPR-Associated (Cas) Genes Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read more here:
CRISPR And CRISPR-Associated (Cas) Genes Market which company is the market leader and how much its sales in 2020 and what it's expected sales for the...

When 26 year-old Yehuda Blonder contracted COVID-19 at a Purim party, he knew it would be bad, he just didnt know how bad.

Blonder has familial dysautonomia (FD), a rare genetic disease with an increased incidence among Jews of Ashkenazi descent. It affects involuntary motion, leading to problems with breath control, blood pressure and the heart. Those affected cannot feel pain or temperature.

FD is one of a number of genetic diseases and mutations more likely to be found among Jewish populations, including Gaucher and cystic fibrosis. Experts cannot say for sure whether people who, like Blonder, have genetic diseases more prevalent among Jews are at a greater risk from the coronavirus.

Even so, many who have them are taking extra measures to ensure their safety during the outbreak.

Interviews with specialists for many of these so-called Jewish genetic diseases show that because of strict social distancing measures, many patients have come out of the Covid-19 outbreak unscathed.

Horacio Kaufmann, a doctor treating people with FD at NYU Langone Health, said two patients died during the Covid-19 epidemic but they were negative for the virus. A disease that causes recurring pneumonia was a worry for Kaufmann.

I dont want to give a sense of false safety, but so far it has not been as devastating as we thought it could have been, Kaufmann said.

The same is true for what Ari Zimran, senior physician at the Gaucher unit at Shaare Zedek Medical Center in Jerusalem, is seeing in his type 1 patients. This disease is the most common among Ashkenazi Jews. About one in about 850 are afflicted.

(Courtesy Ari Zimran)

Ari Zimran, senior physician at the Gaucher unit at Shaare Zedek Medical Center in Jerusalem, standing, center, with Gaucher unit team.

In a draft article on the relationship between Gaucher disease and Covid-19 accepted by the Internal Medicine Journal, Zimran and his team wrote they suspected increased levels of glycosphingolipids due to the disease promoted immune tolerance to the virus.

Zimran has a cohort of approximately 550 patients, including those from Australia. Of the few that contracted Covid-19, none needed to be ventilated.

A pregnant 24-year-old woman with Gaucher disease in the Hasidic New York community, one of the hardest hit areas by Covid-19, had two days of a mild flu like infection. She recently gave birth without any difficulties, Zimran said.

Jews of Iranian and Iraqi descent have developed their own hereditary diseases, including salt losing disorder multiple hormone deficiency and hereditary inclusion body myopathy (HIBM). HIBM causes progressive skeletal muscle weakness and confines those in advanced stages to wheelchairs.

For Daniel Darvish, co-founder of Advancement of Research for Myopathies in Encino, Calif., and a HIBM patient himself, Covid-19 has affected his professional and personal life more than the average person.

The laboratory he works out of has been converted to a Covid-19 testing center. Darvish is unable to work on finding a cure for his own disease. On top of that, the 52-year-old is in a wheelchair and his lung capacity is lower than normal, so hes been forced to quarantine at home for the last 10 weeks.

After a while it gets to affect your mood and affects almost everything in life, Darvish said.

Aggressive genetic screening, in part, has reduced the Jewish patient population with rare diseases. However, people arent getting tested for many of these genetic disorders because of concerns over Covid-19 transmission even with the availability of telehealth.

According to Harry Ostrer, a professor in the departments of pathology and pediatrics at the Albert Einstein College of Medicine, about 1 in 40 Jewish people are carriers for a mutation on the gene BRCA 1 and 2 that increases the risk for breast, ovarian and prostate cancer.

Results for those who want to know their risk of developing cancer may be delayed. Elective procedures, such as mammograms and ultrasounds, which detect cancer early, arent occurring as frequently. Medical practices are also downsizing in the wake of Covid-19.

A number of people are falling through the cracks, Ostrer said.

Yehuda Blonder escaped that unhappy fate. He said he was exposed to the virus at a Purim party with 250 people March 9 and a week later at work on March 16. He got his results March 24: he was positive. On the tenth day after testing positive, he encountered breathing issues and needed to use an oxygen concentrator.

A few weeks later, his throat started hurting and his pediatrician put him on antibiotics as a precaution. It took six weeks for Blonder to fully recover. He said he learned his lesson.

Until other people say that youre not allowed to Im not listening to anyone and Im going to do my own thing, Blonder said he thought at the time. Unfortunately, that backfired a little bit.

Blonder is now fully recovered from COVID-19. Now, he and his family are taking all the necessary precautions to stay safe. Hes working from home and staying indoors as much as he can. An avid biker, he occasionally takes a ride around Prospect Park.

Im lucky, Blonder said. I still pray, I still do all the important stuff. Im still the same person before and after.

Hawkin Miller is a journalist in Los Angeles.

Continue reading here:
Do Jewish genetic diseases increase the risk of COVID-19? - Forward

Sarepta Therapeutics (NASDAQ:SRPT)'s stock had its "buy" rating reaffirmed by investment analysts at Robert W. Baird in a report released on Friday, TipRanks reports. They currently have a $192.00 target price on the biotechnology company's stock. Robert W. Baird's target price suggests a potential upside of 35.93% from the company's previous close.

Other analysts also recently issued research reports about the stock. BidaskClub raised shares of Sarepta Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, May 7th. Nomura Securities reaffirmed a "buy" rating and set a $230.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, February 25th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $217.00 price objective (up previously from $211.00) on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Oppenheimer reissued a "hold" rating on shares of Sarepta Therapeutics in a research report on Thursday, May 7th. Finally, SVB Leerink reaffirmed a "buy" rating and set a $216.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twenty-four have given a buy rating to the stock. The company has an average rating of "Buy" and a consensus target price of $193.05.

Shares of NASDAQ SRPT opened at $141.25 on Friday. The stock has a fifty day moving average price of $112.04 and a 200 day moving average price of $112.85. The company has a market cap of $9.91 billion, a P/E ratio of -16.00 and a beta of 1.87. Sarepta Therapeutics has a 12-month low of $72.05 and a 12-month high of $158.80. The company has a current ratio of 8.31, a quick ratio of 7.75 and a debt-to-equity ratio of 0.66.

Hands down, the biggest profits in 2020 will go to investors who own these three stocks. Claim your free copy of my Breakthrough Stock special report...

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.17) by $1.94. The company had revenue of $113.67 million during the quarter, compared to the consensus estimate of $118.18 million. Sarepta Therapeutics had a negative return on equity of 64.67% and a negative net margin of 160.96%. The company's revenue was up 30.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.07) earnings per share. On average, sell-side analysts forecast that Sarepta Therapeutics will post -8.44 EPS for the current fiscal year.

In other news, Director Richard Barry sold 30,000 shares of the company's stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $141.26, for a total transaction of $4,237,800.00. Following the completion of the transaction, the director now directly owns 3,163,813 shares of the company's stock, valued at $446,920,224.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $116.89, for a total value of $584,450.00. Following the sale, the director now owns 18,792 shares in the company, valued at $2,196,596.88. The disclosure for this sale can be found here. 6.60% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of SRPT. Amundi Pioneer Asset Management Inc. increased its position in Sarepta Therapeutics by 32.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology company's stock worth $18,428,000 after buying an additional 38,194 shares during the period. DNB Asset Management AS acquired a new position in shares of Sarepta Therapeutics during the fourth quarter valued at $1,386,000. Zeke Capital Advisors LLC grew its position in shares of Sarepta Therapeutics by 10.1% during the fourth quarter. Zeke Capital Advisors LLC now owns 5,343 shares of the biotechnology company's stock worth $689,000 after acquiring an additional 491 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter worth about $860,000. Finally, Janney Montgomery Scott LLC lifted its position in Sarepta Therapeutics by 7.7% in the 4th quarter. Janney Montgomery Scott LLC now owns 5,312 shares of the biotechnology company's stock valued at $685,000 after purchasing an additional 382 shares during the last quarter. Hedge funds and other institutional investors own 93.76% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: Federal Reserve

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected]

8 Stocks You Can Count On During Any Crisis

Depending on how you look at it, the economic outlook is getting cloudier or clearer.

The argument for a cloudy economy is easy to make. Multiple times of day we hear about more Americans testing positive for the novel coronavirus. The worldwide number of positive tests exceeds one million. And unfortunately, it will go higher. We just dont know by how much.

But there are two parts to this ongoing situation. The first is the real-time science experiment as the world attempts to flatten the curve. The other is the very real economic impact. And the numbers of the economic carnage are coming in faster than any significant evidence of a flattening curve.

The number of unemployed now exceeds six million and will only rise. The government is throwing everything including the kitchen sink at the problem. But its an experiment in real-time. We wont know the results for some time.

But even while we wait for a new normal to return, there are ways for you to profit. There are companies that are keeping our economy going now, and have a business model that sets them up well for success after the pandemic is over.

View the "8 Stocks You Can Count On During Any Crisis".

Follow this link:
Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Robert W. Baird - MarketBeat

Global Regenerative Medicine Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Regenerative Medicine Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=55&RequestType=Sample

Regenerative Medicine Market is valued at around USD 16148.16 Million in 2017 and expected to reach USD 74831.35 Million by 2024 with the CAGR of 22.27% over the forecast period.

Regenerative Medicine market report published by the Brandessence Market Research and Consulting Pvt. Ltd. provides the detail information about regenerative medicine market from various aspects. This report consists of drivers, restrains, Opportunities which help the market to grow over the analysis period and recent trends which support the growth of market. This report consists of regional segmentation with of Product Type, application, therapy.

Regenerative medicines are those medicines which are used to repair, regenerate, and replace the tissues or organs damaged due to disease, injury or natural aging. Regenerative medicines are used in the treatment of various disorders such as orthopedic, neurodegenerative, oncology and others. These medicines help in the restoration of natural functioning of the organs and tissues. Regenerative medicines can also be used for the treatment of various chronic and genetic disorders, it also helps in the treatment of organ transplant which has reduced the rejection cases to a major extent.

There are various factors driving the growth of the regenerative medicine market, one of the major driving the growth of the market are increased prevalence of various chronic and genetic diseases over the period of time. Moreover, increase in technological advancement has also help in the development of effective and better therapies for the treatment of chronic disorders. Furthermore, the increased burden of these diseases has increased the demand of various effective medications which led to the increase in the regenerative medicine market. Increased research on stem cells has given a new direction to the regenerative medicines an expected to create various opportunities over the forecast period. However, high cost of treatment and stringent government regulations are expected to inhibit the growth of regenerative medicines over the forecast period.

Global regenerative medicines market report covers prominent players like Stryker Corporation, Cook Biotech Inc., Vericel Corporation, DePuy Synthes, Inc. Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, Inc., NuVasive, Inc., Acelity (KCI Concepts), Zimmer Holdings, Inc., Integra LifeSciences, C.R. Bard and others.

By Product Type

Cell-based productsAcellular products

By Application

Orthopedic & Musculoskeletal DisordersCardiologyDermatologyDiabetesCentral Nervous System DisordersOthers

By Therapy

Cell therapyGene therapyTissue engineeringImmunotherapy

By Region

North AmericaU.S.CanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilMexicoMiddle East and AfricaGCCAfricaRest of Middle East and Africa

Regenerative Medicine Market Key PlayersStryker CorporationCook Biotech Inc.Vericel CorporationDePuy Synthes, Inc.Medtronic, Inc.Organogenesis Inc.Osiris Therapeutics, Inc.NuVasive, Inc.Zimmer Holdings, Inc.Integra LifeSciencesOthers

Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=55&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Regenerative Medicine Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Regenerative Medicine Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Regenerative Medicine Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Regenerative Medicine Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Regenerative Medicine Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Regenerative Medicine Market.

Market Forecast: Here, the report offers a complete forecast of the Global Regenerative Medicine Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Read more here:
COVID 19 PANDEMIC: Regenerative Medicine Market Strategies and Insight Driven Transformation 2020-2025 - Cole of Duty

Pharmacogenetic test, also known as drug-gene test is used to study and determine the interactions of drug and the genetic make-up of the individual. It has been observed that different people react differently with drugs according to the expression of the genes induced by the drug. The effect of the drug largely depends on the age, lifestyle, environmental conditions and other medications taken by the individual. Such factors are considered in the pharmacogenetic tests to prescribe the right medication and treatment option to the patient. Pharmacogenetic tests aid the medical professional to choose the best medicine for the person undertaking the test. Pharmacogenetic tests search for the gene variants that may be responsible for influencing the effect of the drug and thereby helps to determine the degree of effect a drug has on the individual. Pharmacogenetic tests are easy and reliable and require blood or oral swab as the sample material. This evidence-based medication management is gaining recognition for specificity and sensitivity detection. Direct-to-customer services are emerging in the pharmacogenetic test market lately, which facilitates easy result access in a smart device.

Request to Sample report @ https://www.persistencemarketresearch.com/samples/27505

The increasing evidence of influence of genes on medications drives the pharmacogenetic test market. Moreover, the rising demand for personalized medicines and precision diagnosis is expected to favor the expansion of the pharmacogenetic test market over the forecast period. Increasing number reimbursement policies for pharmacogenetic tests by insurance companies is expected to influence the growth of pharmacogenetic tests in the market. Increasing healthcare expenditure and higher adoption of advance products in developed and high-income countries is expected to fuel the growth of pharmacogenetic tests market over the forecast period. On the contrary, limited evidence for clinical utility and uncertainty regarding the benefits of the pharmacogenetic tests hamper the growth of pharmacogenetic tests in the market. Additionally, higher cost associated with the pharmacogenetic tests are expected to restrict the mass adoption of the product. Medical and genomic expert is required to the interpretation of the results provided by pharmacogenetic tests which currently have limited access, creating a restraint for expansion of pharmacogenetic test market.

Based on product type, global pharmacogenetic testing market is segmented into:

Based on sample, global pharmacogenetic testing market is segmented into:

Based on therapeutic area, global pharmacogenetic testing market is segmented into:

Based on distribution channel, global pharmacogenetic testing market is segmented into:

Request For TOC @ https://www.persistencemarketresearch.com/toc/27505

The global pharmacogenetic testing market is expected to witness fast growth over the forecast period due to increasing demand for personalized medicines. On the basis of product type, array-based tests are anticipated to grow with high CAGR in pharmacogenetic test market over the forecast period. Oncology segment in therapeutic area is projected to account for maximum share in terms of revenue in the pharmacogenetic test market owing to the increasing focus and higher expenditure on cancer research. On the basis of distribution channel, hospital pharmacies segment is expected to contribute major revenue share in the pharmacogenetic testing market over the forecast period.

On the basis of geography, the global pharmacogenetic test market is split into seven key regions viz. North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa. Region wise, North America is anticipated to be the leader in the global pharmacogenetic test market owing to the higher healthcare expenditure coupled with increasing number of manufacturers in the region. Europe is estimated to represent high incremental opportunities between 2018 and 2028 in the pharmacogenetic test market owing to increasing adoption of the products by end users because of higher spending on healthcare. However, MEA and Latin America are expected to witness stagnant growth in the pharmacogenetic test market owing to the absence of manufacturers in the region and lower healthcare expenditure.

Some of the key players operating in the pharmacogenetic test market are ,

For in-depth competitive analysis, buy [emailprotected] https://www.persistencemarketresearch.com/checkout/27505

Excerpt from:
Impact of COVID-19 pandemic on Pharmacogenetic Tests Market Structure and Its Segmentation During Forecast 2018 2028 - Cole of Duty

Few would question the benefits of a medical profession which reflects the socio-demographic make-up of New Zealand. Our medical schools are now boosting Mori, Pasifika and rural student numbers but have they got the balance right? MARTIN VAN BEYNEN reports.

Harry* is a bright and social 18-year-old who was always passionate about becoming a doctor. He was brought up in a well-off home by professional parents but family issues meant life was no bed of roses.

He completed the first year health science course at the University of Otago last year with an A+ average grade and also managed a top score in the required University Clinical Aptitude Test (UCAT). He was absolutely gutted and so were his parents when he was not accepted into Otago Medical School.

Incredibly, his academic results were not good enough. His disappointment was not helped by students with far lower grades and poorer UCAT results being accepted under special categories including Mori and Pasifika, rural and low socioeconomic.

Harry, of European descent, was not alone in his disappointment. Other European and Asian students faced similar setbacks. At least one family has threatened legal action.

READ MORE:* She aspired to be a doctor at 10, to 'make a point' that Mori can * We need more diversity in our health system - entrance schemes help* Emails reveal Otago and Auckland's med school meddling * Auckland and Otago medical schools undermine Waikato bid* Record numbers of Maori doctors graduate from med school

Its a touchy subject. Few would disagree that elite professions like medicine should reflect the socio-demographic make-up of the general population. Evidence suggests that doctors who have more things in common with their patients will be more empathetic and have more success in diagnosis and getting patients to follow recommended treatments.

But have the medical schools gone too far in trying to redress the balance by squeezing out a growing number of general students? And have entry requirements become too easy to manipulate?

For a long time the medical school intake from some sections of society, notably Mori and Pasifika, was much lower than their proportion of the population.

Only a decade ago, a mere 7.6 per cent of new domestic medical students at Otago identified as Mori and 2.7 per cent as Pasifika. The ramifications show up in the current medical workforce in which only 3.4 per cent are Mori and 1.8 per cent Pasifika. Their respective proportions of the total population are about 15 per cent and 8 per cent.

However, a big change was seen after more robust affirmative action policies were implemented at medical schools after 2010. By 2016 Mori and Pasifika students entering Otago Medical School had increased by 179 per cent Mori were about 16 per cent of domestic students and Pasifika students counted for 5.6 per cent.

One group, however, showed little improvement. In 2010 only 2.4 per cent of Otago medical students had attended a secondary school with a socioeconomic decile of less than four.

By 2016, the percentage had grown to 4.7 per cent.

Wiremu*, now training to be a general practitioner, was one of those students who benefited from affirmative policies designed to increase Mori in the medical workforce. A product of kohanga reo and a low decile Mori immersion primary school, he had a flair for science and wanted to work with people.

His low decile high school had not prepared him well for the highly competitive intermediate year at Auckland University, but he worked his guts out and was accepted into its medical school.

His life experience in different sections of the community, including gang families, enables him to relate to patients better than a book-smart, nerdy type from a privileged background, he says.

As a junior doctor, he was often able to get through to certain Mori patients just by saying his name.

Supplied

Some people cant see the difference between equity and equality," says a junior doctor.

They suddenly realised there was a Mori person on the other side. You just have to see their face when I say Kia Ora Im Wiremu some of them go, True Bro I thought you were Pkeh. In certain circumstances we will have a chat in Mori and obviously that's useful. Then we have a brief introduction period, you get to know the other person. Pronouncing someones name correctly is massive.

He says getting more Mori into medical schools wont fix the inequities in health outcomes but it will help.

Some people cant see the difference between equity and equality. Ive learned so much about why Mori are the way we are today. Sometimes you have to direct more resources to some people for outcomes to be equal.

Some students manipulate the system, but they are a small minority, he says.

For this years intake, Otago had 202 places available for first year students entering from its intermediate year. (Otago does not take first year students from other universities).

Of those, 120 were given to those entering under a raft of categories.

Of those, 58 were Mori, 20 were Pasifika, 1 Mori/Pasifikaand 29 entered through the rural gate. Eleven students went in under the low socio-economic category and one under a new refugee category. That left only 82 general entry places (40 per cent).

As well as the 202 places for first year students, Otago medical school fills another 80 places with graduates. Overall for 2020, Mori and Pasifika make up 32 per cent of students starting at the school, while 14 per cent have rural backgrounds, 4 per centlow socioeconomic, and 1per cent refugee.

Auckland medical school shows a similar pattern. For the 2020 year it had 185 places for first year health science or bio-medicine students. Mori and Pasifika took up 52 places, rural got25, disabled 2, low socioeconomic 5 and refugee1. That left 101 places (55 per cent) for general entry students.

Looking at percentages for the 2020 intake, Mori and Pasifika students took up nearly 40 per cent of the places at Otago for first year health science students and 28.1 per cent of the total places for first year students at Auckland.

At Otago that meant general entry students had to get, as one student put it, ludicrously high grades to be accepted. In fact candidates needed at least a 94 per cent average mark for their seven papers to get an offer.

The father of a European student who missed out on this years intake at Otago despite stellar marks says he can understand why district health boards and central government want the medical workforce to be representative.

Where I have difficultyis reconciling that with students who would make wonderful doctors and have extremely high marks being lost to the medical profession.

The average mark for the sub-category entrants is not held by the university and it was not able to provide it before deadline.

However, sub-category entrants must get a 70 per cent minimum for each paper. Those who achieve an average of at least 70 per cent can be admitted with individual subject marks under 70 per cent so long as the admissions committee is satisfied about their academic ability to complete the programme.

At Otago, a candidates overall UCAT score does not count in the assessment by the admissions committee but general candidates must score in the top 80 per cent of results for verbal reasoning and in the top 90 per cent for situational judgement.

Suppled

This could hurt:Medicine does not need society's brightest students, says a top medical educator.

Critics say the low thresholds are farcical because no-one with good enough grades to be a doctor will go below the thresholds. The university says it uses the scores when choosing between candidates who are otherwise very similar.

The thresholds do not apply to Mori and Pasifika candidates. They are assessed by reference to specific material provided by applicants about their engagement with their communities.

In Auckland, admission is based on an interview (25 per cent), first year marks (60 per cent), and the UCAT result (15 per cent).

Otago University cannot say how many Mori and Pasifika students would have met the grades required by successful general applicants in this years intake, but Professor Paul Brunton, Pro-Vice-Chancellor, Health Sciences says if affirmative action had not been undertaken both Mori and Pasifika students would have been significantly under-represented in this years class compared with the make-up of New Zealand society.

Does the medical school have a cap on sub-category students?

Brunton says the Education Act states affirmative action places can only be offered where a relevant category of applicant would otherwise be under-represented in the medical programme.

To date, the number of sub-category students we have been able to admit continues to be well below the needs of the health workforce.

The Government funds 55 rural places at each of the universities of Otago and Auckland, he says.

Medical school applicants at Otago need to meet a number of requirements to be successful under the various subcategories.

The Mori and Pasifika category requires students to verify their ancestry by, for instance, an iwi registration document or, for Pasifika, a community leaders endorsement.

Applicants under the rural category can hail from places such as Helensville and Pukekohe near Auckland, Lincoln and Rangiora on the outskirts of Christchurch and Featherston, Greytown and Martinborough near Wellington. They also include Queenstown Bay, Frankton, Cromwell and Wnaka.

Under the low socioeconomic category, candidates must have attended a decile one to three secondary school during Years 11, 12 and 13. Parental income is not considered.

JOHN KIRK-ANDERSON/STUFF

Some of Jordan Tewhaiti-Smith's relatives - including his dad - are Mongrel Mob members. They were also his biggest supporters while he studied to become a doctor. (Video first published in December 2019)

In order to apply under the refugee sub-category, candidates for admission must have either been granted refugee status in New Zealand, or have parents/primary guardian(s) who have been granted refugee status.

Affirmative action is always controversial. Critics say it breeds resentment, stigmatises those students who avail themselves of the special categories and lowers the standards and prestige of an institution.

One of the objections is that it can give an unfair advantage to privileged students who actually have little in common with the minorities with whom they claim to have some genetic link. In other words, a Mori student from a relatively privileged home could be admitted over a European or Filipino student from a poorer home despite their better marks.

During his first presidential campaign, Barack Obama, said his two daughters who have had a pretty good deal should not benefit from affirmative action, particularly when they were competing with poor white students.

Some claim the system is open to abuseby wealthy students with a distant relative who is Mori orPasifika..

"These kids are attending private schools and are being allowed into medical school without achieving like the others must. It is not achieving the aims of helping Mori, says one parent.

Another parent asked if patients were better served by doctors who were"empathetic and more academic" regardless of ethnicity.

Professor Peter Crampton, whose parents immigrated from England to New Zealand when he was 12, and who worked as a GP in Porirua, near Wellington, is one of the main architects of the Mirror on Society policy at Otago University.

A former dean of the Otago Medical School and now professor of public health in Khatu Centre for Hauora Mori, he doesnt regard the issues around special entry into medical school as highly sensitive.

He says the purpose of the university is to produce a health workforce that meets the needs of society.

The-Southland-Times

Peter Crampton, aprofessor of public health, says medical schoolsselect students "for things we can't teach".

Doctors who belong to a rural or ethnic minority are more likely to serve those communities and provide the care that is not like the care provided by others.

He draws parallels to the dearth of female doctors in the medical workforce in previous decades.

It was thought men do that job very well and although we think of that as quaint and old fashioned, its not that long ago.

Mori doctors treating Mori patients could lead to better outcomes for multiple reasons, both interpersonal and because of the way systems are set up, he says.

He agrees no guarantee exists that students admitted under the sub-categories will go on to work in those areas and says its too early to tell whether the special entry scheme is helping to improve outcomes for Mori and Pacific patients.

We dont put on any of our students, any of them, any sort of moral weight to do a particular thing.

No affirmative system will have perfect rules and perfect compliance, he says. Defining a student's rural credentialssounded simple but coming up with a transparent and fair system was tricky.

He doesnt acceptthat students being admitted under the Mori or Pasifika sub-categories, who look European and have suffered none of the deprivations of low socioeconomic Mori or Pasifika, should not be allowed to take advantage of the easier route into medical school.

Nor does he agree that if Mori or Pasifika patients are to benefit from an affinity with the doctor, the doctor should look a bit like them.

If you are saying it would help if you look Mori I reject your framing entirely. Would it help if you looked gay?

We want the health workforce to broadly reflect the communities being served so that when you come into contact with the health force, whatever that touch point might be, there is some chance that system has been influenced by health professionals who share your world view, your ethnic affiliation or your gender and you meet a health professional who you might identify with and makes you feel at home within that system.

He finds the allegation that European-lookingstudents from well-off homes with slight Mori or Pacific ancestry are rorting the system hard to get a handle on.

You're conjuring up a phenomenon that encapsulates a world view that I would like to deconstruct.

He says Mori and Pacific students have a different socio-economic profile to general entry students although it is true the research in 2016 showed little movement in admitting more students from lower decile schools.

Any system of exclusion or inclusion is going to run into its difficulties at the margins with definitions.Its not perfect or watertight. Does that discredit the system,do we throw out a system because some people might not be eligible? The health workforce needs more Mori-Pacific students. We have not specified if they be rich or poor.

Although Mori and Pasifika students coming through the intermediate year pathway into Otago medical school were exceeding their proportion of the general population, the proportion of those groups in the medical workforce realistically will not catch up not in our lifetimes.

The marks required by general entry students was very high but people needed to remember why are we are doing this.

The high marks phenomenon is an artefact of selection processes. If I ask people, what do you like to see in your doctor? they say good communicator, honesty, compassion, altruism, along those lines. They never say we want them to have had straight As at school and through university.

We can't easily measure what we need to measure. Medicine does not need society's brightest students, it benefits from them but doesn't need them. That is an artefact of career aspirations occurring over decades.

We select people to meet certain characteristics we select them for things we can't teach. It is a demanding and difficult course and it needs people who are bright, capable and highly motivated. That is not the same as saying we need the top academic students. We don't have to have them.

Medical schools were sick of using marks.

He believed the UCAT thresholds were meaningful and helped exclude candidates who could be brilliant lab scientists but no good at face-to-face medicine.

So what would he say to Harry with his tremendous marks and who had his heart set on medicine?

Iunderstand their bitter disappointment and in my counselling I strongly encourage them to explore other options. So many young people base their sense of their identity and ambition on a particular academic pathway and feel quite devastated when that is not achieved. The world is full of amazing career opportunities for the academically capable."

Does he understand their resentment?

Thats where I come back to the policy and its intention. The policies are clear. To me personally and many colleagues in the university it's completely unacceptable that we have a health workforce devoid of Mori. We are rectifying that situation. The problem is that high marks have become the passport and because I've got high marks I should be a doctor.

*Notreal names.

See original here:
Medical School: Who gets in and why - Stuff.co.nz

CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Company and the United States Army Medical Research Institute of Infectious Diseases (U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the Department of Defenses lead laboratory for medical biological defense research, have entered into a Cooperative Research and Development Agreement (CRADA). The purpose of the CRADA is to jointly identify antisense oligonucleotides using Sareptas proprietary phosphorodiamidate morpholino oligomer (PMO) platform with activity against SARS-CoV-2 for the potential treatment of COVID-19.

Previously published clinical and preclinical studies of Sareptas RNA technology have found evidence of antiviral activity of Sareptas PMO technology in coronaviruses and other viruses.i,ii,iii, iv Pursuant to the CRADA, Sarepta will design, synthesize, manufacture and provide to USAMRIID multiple peptide-conjugated PMO (PPMO) constructs based on genetic sequencing of SARS-CoV-2 for COVID-19. USAMRIID will evaluate the constructs on characterized wild-type SARS-CoV-2 viruses for their potential to inhibit viral infection. Based on the results, Sarepta and USAMRIID will consider collaborative funding proposals to advance the development of treatments for COVID-19.

We should all be proud and grateful that in collaboration with health agencies, many innovative companies across the biopharmaceutical ecosystem have mobilized to fight and solve this COVID-19 pandemic, investing significant resources to rapidly build diagnostics, find treatments, and develop effective vaccines, said Doug Ingram, Sareptas President and Chief Executive Officer. While Sareptas mission to rapidly advance treatments for rare and often fatal genetic disease is focused, unwavering and undeterred, we cannot ignore the impact of this global pandemic on human health, and have answered the call to contribute our scientific expertise and provide our technology in the race to develop an effective treatment for COVID-19. Indeed, we have already built and manufactured therapeutic PPMO constructs and are providing them now to USAMRIID for testing and evaluation.

About the U.S. Army Medical Research Institute of Infectious DiseasesFor over 50 years, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutionsvaccines, drugs, diagnostics, and training programsthat benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agencys Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command. For more information, visit http://www.usamriid.army.mil

AboutSarepta TherapeuticsAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Sarepta Forward-Looking StatementThis press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the purpose of the CRADA to jointly identify antisense oligonucleotides using Sareptas PMO platform with activity against SARS-CoV-2; the parties commitments under the CRADA; Sarepta and USAMRIIDs plan, subject to an evaluation of the constructs, to consider collaborative funding proposals to advance the development of treatments for COVID-19; the potential of the collaboration between Sarepta and USAMRIID to develop a treatment for COVID-19; and Sareptas mission to rapidly advance treatments for rare and often fatal genetic disease.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sareptas control. Known risk factors include, among others: the expected benefits and opportunities related to the CRADA may not be realized or may take longer to realize than expected due to challenges and uncertainties inherent in product research and development; in particular, the collaboration may not result in any viable treatments suitable for commercialization due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, the results of research may not be consistent with past results or may not be positive or may otherwise fail to meet regulatory approval requirements for the safety and efficacy of product candidates, possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sareptas product candidates; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Companys business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sarepta's 2019 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

i NeumanBW, et al. J Virol.2004Jun;78(11):5891-9. Antisense morpholino-oligomers directed against the 5' endofthe genome inhibit coronavirus proliferation and growth.

ii Burrer R, et al. J Virol.2007 Jun;81(11):5637-48. Antiviral effectsofantisensemorpholinooligomers in murine coronavirus infection models.

iii NeumanBW, et al. J Virol.2005 Aug;79(15):9665-76. Inhibition, escape, and attenuated growthofsevere acute respiratory syndrome coronavirus treated withantisensemorpholinooligomers.

iv HealdAE, et al. AntimicrobAgentsChemother.2014 Nov;58(11):6639-47. Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity Against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies.

Read more:
Sarepta Therapeutics Announces Research Agreement with US Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as...

Facing public backlash, government warnings, and private misgivings, more than a dozen publicly traded companies and big businesses have so far announced they have returned, or intend to return, small-business coronavirus relief loans issued by the Small Business Administration.

Under the Paycheck Protection Program launched midnight April 3, businesses can apply for loans with their banks to help them shore up payroll and fund essential expenses, such as rent and utilities. If the businesses follow certain rules, such as using the bulk of the funds to keep employees hired and paid, the loan turns into a forgivable grant.

Over a million businesses large and small applied under the loose guidelines that said companies must have fewer than 500 employees and be able to demonstrate economic injury due to the coronavirus shutdowns.

But after the $350 billion of initial funding started to run dry and publicly traded companies with more access to funds started making headlines for receiving government assistance while smaller businesses were left out, some companies had second thoughts.

The SBA and Treasury Department issued new guidance this week, clarifying that the loans were not intended for companies with access to the equity market. Treasury Secretary Steven Mnuchin warned companies last week that could suffer consequences if they could not certify they were facing economic injury. Companies have until May 7 to return funds "in good faith."

On Tuesday, Mnuchin said companies receiving loans over $2 million would be audited, and warned of potential criminal liability.

Out of the over $900 million received by the 250 public companies that disclosed PPP loans, the total amount returned by the companies is nearly $120 million. Together, the 15 companies have a combined market cap of over $17 billion.

Under the program, the maximum loan size is $10 million, based on payroll calculations. Two firms, Ruths Chris Hospitality Group and J. Alexander's Holdings, received in excess of $10 million because each had two subsidiaries that applied for a separate loan.

Aquestive Therapeutics

Description: Specialty pharmaceutical company and maker of Suboxone, an opioid addiction treatment.

Loan: $4,830,000

Market cap: $139,702,093

Full-time employees: 232

Ballantyne Strong

Description: Holding company whose subsidiaries make cinema equipment, projectors and lighting.

Loan: $3,173,900

Market cap: $23,300,000

Full-time employees: 290

BioLife Solutions

Description: Supplier of cell and gene therapy tools, including design and manufacturing of liquid nitrogen tanks and cryogenic equipment.

Loan: $2,175,320

Market cap: $229,678,262

Full-time employees: Not disclosed

BK Technologies Corporation

Description: Suppliers of two-way radio equipment.

Loan: $2,196,335

Market cap: $30,200,000

Full-time employees: 109

CalAmp Corp.

Description: Sellers of equipment and systems for remotely monitoring vehicles.

Loan: $10,000,000

Market cap: $218,274,636

Full-time employees: 882

Hallmark Financial Services

Description: Property and casualty insurers for businesses and consumers.

Loan: $8,311,000

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Market cap: $56,362,819

Full-time employees: 439

IDT Corporation

Description: Newark, NJ-based telecommunications company that offers service and sells prepaid phone cards.

Loan: $10,000,000

Market cap: $152,360,276

Full-time employees: 1,270

J. Alexander's Holdings, Inc.

Description: Holding company for several casual restaurant chains, including the Stoney River Steakhouse & Grill, Redlands Grill, and Lyndhurst Grill steak chains.

Loan: $15,100,000

Market cap: $66,201,491

Full-time employees: 4,200

Kura Sushi USA, Inc.

Description: American subsidiary of a Japanese sushi chain, with over 400 locations.

Loan: $5,983,290

Market cap: $106,894,657

Full-time employees: 1,400

L.A. Lakers

Description: Los Angeles NBA franchise.

Loan: $4.6 million

Estimated value: $3.7 billion

Nathan's Famous

Description: Casual restaurant chain specializing in hot dogs.

Loan: $1.2 million

Market cap: $253,346,932

Full-time employees: Not available

OptiNose, Inc.

Description: Pharmaceutical company focused on delivering products for treating ear, nose, throat and allergy patients.

Loan: $4,400,000

Market cap: $195,101,189

Full-time employees: 221

Potbelly Corporation

Description: Restaurant chain with nearly 500 locations, specializing in heated sandwiches.

Loan: $10,000,000

Market cap: $72,096,379

Full-time employees: 6,000

Ruth's Hospitality Group

Description: Holding company that owns the chain of high-end Ruths Chris Steak House locations.

Loan: $20,000,000

Market cap: $273,802,586

Full-time employees: 5,740

Shake Shack

Description: Fast casual chain of made-to-order ground beef burgers and its namesake milkshakes.

Loan: $10,000,000

Market cap: $1,912,811,047

Full-time employees: 7,603

Ultralife Corporation

Description: Battery and communications manufacturer.

Loan: $3,459,278

Market cap: $112,523,178

Full-time employees: 573

Wave Life Sciences Ltd.

Description: Clinical-stage genetic medicine company based in Singapore.

Loan: $7,234,890

Market cap: $300,165,896

Full-time employees: 301

Data source: NBC News analysis of SEC filings, FactSquared, Google Finance, Forbes. Last updated: 4/28 4 p.m. ET.

Visit link:
Which companies are returning their PPP loan? Here's the list. - NBCNews.com